Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of apremilast in pediatric plaque psoriasis
2018-002918-12Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Apremilast with Placebo (2 arms). Primary endpoint: Static Physician Global Assessment (sPGA). Started Oct 2018; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2018-002918-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002918-12.